JP摩根美股医疗科技行业药店收益管理最新PBM调查要点201952937页

整理文档很辛苦,赏杯茶钱您下走!

免费阅读已结束,点击下载阅读编辑剩下 ...

阅读已结束,您可以下载文档离线阅读编辑

资源描述

NorthAmericaEquityResearch29May2019PharmacyBenefitManagementTakeawaysfromOurLatestProprietaryPBMSurveyHealthcareTechnology&DistributionLisaC.GillAC(1-212)622-6466lisa.c.gill@jpmorgan.comBloombergJPMAGILLGOMichaelMinchak,CFA(1-212)622-6506michael.minchak@jpmorgan.comAnneE.Samuel(1-212)622-4163anne.e.samuel@jpmorgan.comManagedCare/FacilitiesGaryPTaylor(1-212)622-6600gary.taylor@jpmorgan.comAnthonyMakdessi(1-212)622-3682anthony.makdessi@jpmchase.comJ.P.MorganSecuritiesLLCSeepage35foranalystcertificationandimportantdisclosures.J.P.Morgandoesandseekstodobusinesswithcompaniescoveredinitsresearchreports.Asaresult,investorsshouldbeawarethatthefirmmayhaveaconflictofinterestthatcouldaffecttheobjectivityofthisreport.Investorsshouldconsiderthisreportasonlyasinglefactorinmakingtheirinvestmentdecision.(contactyourJPMsalespersonfordetails).Intermsofbroaderimplications,theoverallsurveypresentsachallengingdichotomybetween92%overallsatisfactionbut61%citingPBMsas“partoftheproblem”withsomefairlyunflatteringfree-formresponses.ThePBMmodelcontinuestoevolve,withagreaterfocusonintegratedhealthinsurer/PBMmodelsthatmanageoverallhealthcarecosts.Whiletheregulatoryenvironmentormarket-drivenchangescouldimpactthebusinessmodelovertheneartomediumterm,therestilldoappeartobeopportunitiesaroundplandesignelementsthatcanhelptodriveimprovingprofitability.CVSHealth/RxChannel(LisaGill)–CVScontinuestoshowhighsatisfactionratesandscoredwellaroundperceivedtransparency.Whilestillearlyonintermsofpromotingtheintegratedoffering,wewouldexpectthistobemoreofafocusinthesellingseasonnextyear,whiletheintegrationdoesnotappearveryconcerningtocustomers.Specialtyremainsanimportantfocusforplansponsors(CVSisthelargestplayer),whileawillingnessofcustomerstoimplementpreferredornarrownetworkscoulddriveincrementalbenefittothecompany’sretailbusinessovertime.OptumRX/ExpressScripts/Ingenio(GaryTaylor)–BothOptumRXandExpresssatisfactionrateshavegenerallytrendedweakerinrecentyears,seeminglyinconsistentwiththeclaimedhighretentionand2020sellingseasonmomentuminourrecentmngtmeetings.Itisencouragingtoseemajoritybeliefinthepotentialoftheintegratedmedical/pharmamodel(Optumhasbeenonthatstrategythelongest),andperhapsnotsurprisingthatANTM’snewIngenioRXclaimsfairlysmallmindshareatthisearlyjuncture.Oursurveyfocusedonseveralkeyareas,including:1)theenvironmentaroundrebates(stillrelativelylowpenetrationaroundpoint-of-salerebates,andbroadcustomerinterestinmanufacturersmovingtoanetpricemodel);2)verticallyintegratedmodels(amajorityofrespondentsbelieveintegratedmodelscandriveoverallhealthcaresavings);3)transparency(citedbyrespondentsasoneofthebiggestconcernsaroundthecurrentPBMpricingmodel);4)viewsonPBMs’roleaspartoftheproblemorthesolution(givenintenseongoingscrutinyarounddrugpricingandtheroleof“middlemen,”amajorityviewthemaspartoftheproblem;5)satisfactionrates(whichremainhighdespiteviewsonthebusinessmodel);6)primarysourcesofpotentialdisruptioninthenextfiveyears(theregulatoryenvironmentandspecialtythemostfrequentlycitedresponses);and7)opportunitiesaroundplandesign(e.g.,mail,specialty,formularymanagement,retailnetworks).2NorthAmericaEquityResearch29May2019LisaC.Gill(1-212)622-6466lisa.c.gill@jpmorgan.comBackgroundWehaveconductedour25thproprietarysurveyofHRexecutivesatlargeemployersacrosstheU.S.,helpingustogainabetterunderstandingofthecurrentthoughtsaroundkeythemesandtrendsrelatedtopharmacybenefits.Surveyswerefieldedelectronicallyby49respondentsthatareresponsibleformakingbenefitdecisionsforleadingU.S.companies(responseratesvariedslightlybyquestion).Inaggregate,therespondentcompaniescomprised~1.0millionU.S.-basedbeneficiariesandhadaggregateannualdrugspendofroughly$1.6billion.Theresponsesfromthissurveybuildonextensiveindustryknowledgewehavegleanedfromvariouscompanies,consultants,andcustomers,aswellaspriorsurveyworkconductedtwiceannuallysince2007(whichwebelieveprovidesforaninterestingcomparisonandallowsustoevaluatetrendsovertime).BroaderImplicationsTheoverallsurveypresentsachallengingdichotomybetween92%overallsatisfactionbut61%citingPBMsas“partoftheproblem”withsomefairlyunflatteringfree-formresponses.ThePBMmodelcontinuestoevolve,withagreaterfocusonintegratedhealthinsurer/PBMmodelsthatmanageoverallhealthcarecosts.Whiletheregulatoryenvironmentormarket-drivenchangescouldimpactthebusinessmodeloverthenextfewyears,therestilldoappeartobeopportunitiesaroundplandesignelementsthatcanhelptodriveimprovingprofitability.CVSHealth/

1 / 37
下载文档,编辑使用

©2015-2020 m.777doc.com 三七文档.

备案号:鲁ICP备2024069028号-1 客服联系 QQ:2149211541

×
保存成功